Ph.D. Jay R. Luly - 15 Jan 2022 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
President and CEO, Director
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Issuer symbol
ENTA
Transactions as of
15 Jan 2022
Net transactions value
+$118,442
Form type
4
Filing time
18 Jan 2022, 05:04:23 UTC
Previous filing
03 Dec 2021
Next filing
15 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Options Exercise $118,442 +10,063 +1.4% $11.77 710,791 15 Jan 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (right to buy) Options Exercise $0 -10,063 -100% $0.000000* 0 15 Jan 2022 Common Stock 10,063 $11.77 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to the option are fully vested and exercisable.